Akanabe H, Ishiguro M, Yagi Y, Ohshima S, Ohmae M, Mori H, Watanabe S, Yasue T
Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):63-9.
A number of studies have shown short term hemodynamic and symptomatic improvement in patients with essential hypertension under treatment with diltiazem. The long-term efficacy of the oral calcium antagonist, diltiazem, remain to be established in patient studies. We evaluated this drug in 70 patients with WHO classification 1-3 hypertension. Diltiazem was tested alone in 25 patients, in combination with diuretics in 14 patients and other drugs in 31 patients with essential hypertension. The fall in blood pressure after oral diltiazem was maximum with 24 weeks and then the fall continued steadily with significant improvement as judged by subjective patients impression in each group. The efficacy ratio of diltiazem was 57.1% in remarkably effective cases, 22.9% in effective, 10% in moderately effective and 10% in not effective cases. And this efficacy ratio was most prominent in other drugs concomitant group, followed by the diltiazem monotherapy group and in the diuretic concomitant use group. We concluded the oral calcium antagonist, diltiazem, is effective in patients with essential hypertension, providing significant blood pressure and symptomatic benefit with long-term treatment.
多项研究表明,接受地尔硫䓬治疗的原发性高血压患者短期血流动力学和症状有所改善。口服钙拮抗剂地尔硫䓬的长期疗效仍有待在患者研究中确定。我们对70例世界卫生组织分类为1-3级高血压的患者进行了该药物评估。25例患者单独使用地尔硫䓬,14例患者与利尿剂联合使用,31例原发性高血压患者与其他药物联合使用。口服地尔硫䓬后,血压下降在24周时最大,然后每组患者主观感觉显示血压持续稳步下降且有显著改善。地尔硫䓬的有效率在显效病例中为57.1%,有效病例中为22.9%,中效病例中为10%,无效病例中为10%。且该有效率在联合其他药物组最为显著,其次是地尔硫䓬单药治疗组和联合利尿剂使用组。我们得出结论,口服钙拮抗剂地尔硫䓬对原发性高血压患者有效,长期治疗可显著降低血压并改善症状。